Cell MedX Corp. is a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with aging and medical conditions including, but not limited to: diabetes, Parkinson’s disease, high blood pressure, neuropathy and kidney function. The Company’s main focus is on continued research and development of its eBalance® Technology and its eBalance® System.
Company profile
Ticker
CMXC
Exchange
Website
CEO
Frank E. Mcenulty
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Sports Asylum, Inc., Plandel Resources, Inc.
SEC CIK
Corporate docs
Subsidiaries
Cell MedX (Canada) Corp. ...
CMXC stock data
Latest filings (excl ownership)
10-Q
2024 Q3
Quarterly report
15 Apr 24
8-K
Unregistered Sales of Equity Securities
4 Apr 24
D
$120.00 k in equity / options / securities to be acquired, sold $45.00 k, 2 investors
26 Mar 24
8-K
Cell MedX Corp. Closes Private Placement Financing
19 Mar 24
DEF 14C
Information statement
6 Mar 24
8-K
Cell MedX Corp. Announces Resignation of Director
28 Feb 24
PRE 14C
Preliminary information
22 Feb 24
10-Q
2024 Q2
Quarterly report
16 Jan 24
8-K
Cell MedX Corp. Announces New CEO and Directors and Debt Settlement
19 Dec 23
8-K
Cell Medx Corp. Announces Full Revocation of British Columbia Cease Trade Order
27 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Nov 23 | Aug 23 | May 23 | Feb 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | May 23 | May 22 | May 21 | May 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Dec 23 | Vahabzadeh Amir | Common Shares | Grant | Acquire A | No | No | 0.007 | 61,755,148 | 432.29 k | 64,975,148 |
29 Dec 23 | daCosta Joao | Common Shares | Grant | Acquire A | Yes | No | 0.007 | 531,687 | 3.72 k | 2,061,687 |
29 Dec 23 | Dwayne Yaretz | Common Shares | Grant | Acquire A | No | No | 0.007 | 1,214,285 | 8.50 k | 1,214,285 |
29 Dec 23 | Jeffs Richard | Common Shares | Buy | Acquire P | No | No | 0.007 | 14,372,285 | 100.61 k | 25,624,313 |
29 Dec 23 | Jeffs David | Common Shares | Buy | Acquire P | Yes | No | 0.007 | 7,500,000 | 52.50 k | 88,959,726 |
29 Dec 23 | Jeffs David | Common Shares | Buy | Acquire P | Yes | No | 0.007 | 7,500,000 | 52.50 k | 81,459,726 |
29 Dec 23 | Jeffs David | Common Shares | Grant | Acquire A | No | No | 0.007 | 73,959,726 | 517.72 k | 73,959,726 |